The Committee for Medicinal Products for Human Use (CHMP) has recently recommended new terms for the market authorization of the medicinal product crizotinib, that is marketed by Pfizer under the brand name Xalkori.
The existing indications for the Xalkori monotherapy included:
The CHMP has adopted two new indications for crizotinib for paediatric patients with anaplastic large cell lymphoma (ALCL) or inflammatory myofibroblastic tumour (IMT). They are:
The European public assessment report (EPAR) will publish the details of its usage. They will be made available in all official European Union languages once the European commission grants market authorisation.